LENZ Therapeutics (NASDAQ: LENZ) insider transactions
In the twelve months to 10 November 2026, executives and directors of LENZ Therapeutics reported 5 open-market sales of 2,728,684 shares ($9.4m) and 3 open-market purchases of 41,181 shares ($365,552), by 5 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 29 October 2026 | Ra Capital Management, L.p. | — | Open-market sale | −2,159,516 | $3.36 | 1,159,823 | Form 4 |
| 29 October 2026 | Ra Capital Management, L.p. | — | Open-market sale | −451,998 | $3.36 | 242,757 | Form 4 |
| 29 October 2026 | Ra Capital Management, L.p. | — | Open-market sale | −107,170 | $3.36 | 57,559 | Form 4 |
| 27 March 2026 | Chevallard Daniel R. | Chief Financial Officer | Open-market purchase | +7,500 | $8.57 | 12,886 | Form 4 |
| 27 March 2026 | Schimmelpennink Evert B. | President, CEO and Secretary | Open-market purchase | +28,089 | $8.95 | 77,289 | Form 4 |
| 27 March 2026 | George Jeffrey P. | Director | Open-market purchase | +5,592 | $8.92 | 5,592 | Form 4 |
| 17 November 2025 | Olsson Shawn | Chief Commercial Officer | Option exercise, 10b5-1 plan | +10,000 | $2.08 | 14,733 | Form 4 |
| 17 November 2025 | Olsson Shawn | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −4,212 | $25.74 | 10,521 | Form 4 |
| 17 November 2025 | Olsson Shawn | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −5,788 | $26.37 | 4,733 | Form 4 |
| 7 November 2025 | McCollum James W | Director | Open-market purchase | +10,500 | $22.79 | 10,500 | Form 4 |
| 7 November 2025 | Chevallard Daniel R. | Chief Financial Officer | Open-market purchase | +20 | $22.71 | 3,208 | Form 4 |
| 7 November 2025 | Chevallard Daniel R. | Chief Financial Officer | Open-market purchase | +2,178 | $22.76 | 5,386 | Form 4 |
| 30 September 2025 | Versant Vantage II GP-GP, LLC | — | Open-market sale | −49,701 | $45.35 | 1,133,842 | Form 4 |
| 30 September 2025 | Versant Vantage II GP-GP, LLC | — | Open-market sale | −34,405 | $45.35 | 821,752 | Form 4 |
| 30 September 2025 | Versant Vantage II GP-GP, LLC | — | Open-market sale | −83,066 | $46.41 | 1,050,776 | Form 4 |
| 30 September 2025 | Versant Vantage II GP-GP, LLC | — | Open-market sale | −57,502 | $46.41 | 764,250 | Form 4 |
| 30 September 2025 | Versant Vantage II GP-GP, LLC | — | Open-market sale | −177 | $47.01 | 1,050,599 | Form 4 |
| 30 September 2025 | Versant Vantage II GP-GP, LLC | — | Open-market sale | −123 | $47.01 | 764,127 | Form 4 |
| 18 September 2025 | Versant Venture Capital VI, L.P. | — | Open-market sale | −49,479 | $41.59 | 1,224,718 | Form 4 |
| 18 September 2025 | Versant Venture Capital VI, L.P. | — | Open-market sale | −24,370 | $41.59 | 876,437 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the LENZ Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.